SUMMIT, N.J., Oct. 21, 2025 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), announced recent data showing that cell-based influenza vaccines offer greater protection in preventing ...
CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting marketing authorization for Flucelvax Tetra (Seqirus Netherlands BV), a ...
The U.S. Food and Drug Administration approved the first facility in the United States to manufacture seasonal influenza vaccine using cell-based technology, according to the HHS. That facility is ...
Hosted on MSN
Flu vaccine performance varies by age, study reveals
New research comparing four different flu vaccines found that the ability of the vaccines to activate cells of the immune system that help to protect against infection varied greatly depending on the ...
A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies. This is an ASCO Meeting ...
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...
Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat ...
Conventional vaccine adjuvants primarily rely on molecular binding and biochemical stimulation to activate immune responses, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback